文献速递胸部肿瘤

厄洛替尼对比长春瑞滨联合顺铂辅助治疗IIIA期表皮生长因子受体阳性非小细胞肺癌的随机II期EVAN研究更新总生存及探索性分析

Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2022-08-26

随机开放标签II期EVAN研究比较厄洛替尼与长春瑞滨/顺铂作为完全切除(R0)后III期EGFR突变阳性非小细胞肺癌辅助治疗的疗效与安全性。更新随访43个月结果显示,厄洛替尼组中位总生存84.2个月 vs 化疗组61.1个月(HR 0.318,95%CI 0.151-0.670),5年生存率分别为84.8%和51.1%。

要点

  • 厄洛替尼组中位OS 84.2个月 vs 化疗组61.1个月,HR 0.318(95%CI 0.151-0.670)。
  • 厄洛替尼组5年DFS在ITT人群为48.2%(95%CI 29.4-64.7),PP人群为46.2%(95%CI 27.6-62.9)。
  • 厄洛替尼组5年生存率84.8% vs 化疗组51.1%。

核心结论

  • 本研究首次证明在R0切除的III期EGFR突变阳性非小细胞肺癌中,厄洛替尼辅助治疗较化疗可带来有临床意义的总生存改善。

研究设计与样本

  • 随机、开放标签、II期EVAN研究,患者1:1随机分配至厄洛替尼组(n=51)或长春瑞滨/顺铂组(n=51)。
  • 厄洛替尼组中位随访54.8个月,化疗组中位随访63.9个月,更新结果报告于43个月随访时。

主要发现

  • 厄洛替尼组中位OS 84.2个月 vs 化疗组61.1个月(HR 0.318;95%CI 0.151-0.670)。
  • 厄洛替尼组5年DFS在ITT人群为48.2%(95%CI 29.4-64.7),在PP人群为46.2%(95%CI 27.6-62.9)。
  • 厄洛替尼组5年生存率84.8% vs 化疗组51.1%。
  • 全外显子组测序分析中,基线共突变频率较高的基因包括TP53、MUC16、FAM104B、KMT5A和DNAH9。
  • 厄洛替尼组中UBXN11的单核苷酸多态性突变与显著更差的DFS相关(P=.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The randomized, open-label, phase II EVAN study investigated the efficacy (disease-free survival [DFS] and 5-year overall survival [OS]) and safety of erlotinib versus vinorelbine/cisplatin as adjuvant chemotherapy after complete resection (R0) for stage III epidermal growth factor receptor (EGFR) mutation+ non-small-cell lung cancer. We describe the updated results at the 43-month follow-up. In EVAN, patients were randomly assigned (1:1) to erlotinib (n = 51) or vinorelbine/cisplatin (n = 51). The median follow-up was 54.8 and 63.9 months in the erlotinib and chemotherapy arms, respectively. With erlotinib, the respective 5-year DFS by Kaplan-Meier analysis was 48.2% (95% CI, 29.4 to 64.7) and 46.2% (95% CI, 27.6 to 62.9) in the intention-to-treat and per-protocol populations. The median OS was 84.2 months with erlotinib versus 61.1 months with chemotherapy (hazard ratio, 0.318; 95% CI, 0.151 to 0.670). The 5-year survival rates were 84.8% and 51.1% with erlotinib and chemotherapy, respectively. In whole-exome sequencing analysis, frequent genes with variants co-occurring at baseline were TP53, MUC16, FAM104B, KMT5A, and DNAH9. With erlotinib, a single-nucleotide polymorphism mutation in UBXN11 was associated with significantly worse DFS (P = .01). To our knowledge, this study is the first to demonstrate clinically meaningful OS improvement with adjuvant erlotinib compared with chemotherapy in R0 stage III EGFR+ non-small-cell lung cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yue D, Xu S, Wang Q, et al. Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer. J Clin Oncol. 2022. PMID: 36027483. doi:10.1200/JCO.22.00428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。